Journal of Biomedicine and Practice – Biomeditsina va amaliyot jurnali Ҷилди 9 № 2 (2024)
EFFECTIVENESS AND SAFETY OF BROLUCIZUMAB IN TREATING DIABETIC MACULAR EDEMA
ХАМИДУЛЛАЕВ Фирдавс Фаридунович, НОРМАТОВА Наргиза Миршавкатовна, НЕМАТУЛЛОЕВ Тухтасин Комилжонович
Аннотатсия
While current treatments targeting vascular endothelial growth factor (VEGF) show effectiveness, there's still a call for more therapeutic options that can either enhance treatment outcomes or lessen the need for frequent injections and monitoring in diabetic macular edema (DME) patients. This study aims to assess the performance and safety of brolucizumab compared to aflibercept, administered every four weeks to individuals with DME. Conducted over 52 weeks and double-blinded, this phase 3 trial included adults new to treatment and those who had previously undergone anti-VEGF therapy, with data collection from September 2019 to March 2020 and analysis from April 2020 to February 2021. The intervention involved administering 6 mg of brolucizumab or 2 mg of aflibercept via intravitreal injection every four weeks. Participants were assigned in a 2:1 ratio to either treatment, focusing on primary outcomes like the change in best-corrected visual acuity by week 52, and secondary outcomes including improvements in the Diabetic Retinopathy Severity Scale score, absence of subretinal and intraretinal fluid, changes in central subfield thickness, and overall safety. The trial randomized 217 participants, with a majority being male and an average age of 60.7 years. Brolucizumab showed comparable efficacy to aflibercept regarding visual acuity improvement and demonstrated superiority in reducing subretinal and intraretinal fluid and central subfield thickness. The occurrence of intraocular inflammation, retinal vasculitis, and vascular occlusion was slightly higher in the brolucizumab group, with one case of retinal artery occlusion. Ultimately, the study found no significant difference in visual outcomes between the two treatments, though brolucizumab exhibited certain anatomical advantages without raising new safety issues.
Диабетический макулярный отек (DME), Сосудистый эндотелиальный фактор роста (VEGF), Бролуцизумаб, Афлиберцепт, Внутриглазные инъекции, Улучшение остроты зренияDiabetic Macular Edema (DME), Vascular Endothelial Growth Factor (VEGF), Brolucizumab, Aflibercept, Intravitreal Injection, Visual Acuity ImprovementDiabetik makulyar shish (DME), Vaskulyar endotelial o'sish faktori (VEGF), Brolutsizumab, Aflibersept, Intravitreal in'ektsiya, Ko'rish aniqligini yaxshilash
Манбаи метамаълумот: бойгонии OAI-PMH-и маҷалла · Sindex матни пурраро нигоҳ намедорад, ба манбаъ пайванд медиҳад.